Emerging Australia oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced a license agreement for its lead pipeline candidate Cantrixil (TRX-E-002-1).
Kazia Therapeutics signs global agreement for lead candidate
March 4, 2021 BioPharmaLatest NewsAustralian BiotechLatest Video
New Stories
-
Gilead announces eight recipients of inaugural Community Grants Program
March 28, 2024 - - Latest News -
Groups call for a new approach to reviewing and funding cancer medicines
March 28, 2024 - - Latest News -
Auditor General extends time to contribute to PBS performance audit
March 28, 2024 - - Latest News -
Reform bill redefines political donation and could exclude the industry from participating
March 27, 2024 - - Latest News -
NZ Government delivers funding boost for patients travelling to health treatment
March 27, 2024 - - Latest News -
Clarity Pharmaceuticals launches $121 million fully underwritten equity raising
March 26, 2024 - - Australian Biotech -
More states announce RSV programs as families call for national action
March 26, 2024 - - Latest News